Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.

Gauthier YP, Tournier JN, Paucod JC, Corre JP, Mock M, Goossens PL, Vidal DR.

Infect Immun. 2009 Mar;77(3):1197-207. doi: 10.1128/IAI.01217-08.

2.

Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.

Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, Baker JR Jr.

Infect Immun. 2007 Aug;75(8):4020-9.

3.

Anthrax spores make an essential contribution to vaccine efficacy.

Brossier F, Levy M, Mock M.

Infect Immun. 2002 Feb;70(2):661-4.

4.

The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.

Welkos S, Little S, Friedlander A, Fritz D, Fellows P.

Microbiology. 2001 Jun;147(Pt 6):1677-85.

PMID:
11390699
5.

Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.

Skoble J, Beaber JW, Gao Y, Lovchik JA, Sower LE, Liu W, Luckett W, Peterson JW, Calendar R, Portnoy DA, Lyons CR, Dubensky TW Jr.

Infect Immun. 2009 Apr;77(4):1649-63. doi: 10.1128/IAI.00530-08.

6.

Poly-gamma-d-glutamic acid and protective antigen conjugate vaccines induce functional antibodies against the protective antigen and capsule of Bacillus anthracis in guinea-pigs and rabbits.

Lee DY, Chun JH, Ha HJ, Park J, Kim BS, Oh HB, Rhie GE.

FEMS Immunol Med Microbiol. 2009 Nov;57(2):165-72. doi: 10.1111/j.1574-695X.2009.00595.x.

7.

Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.

Huang J, Mikszta JA, Ferriter MS, Jiang G, Harvey NG, Dyas B, Roy CJ, Ulrich RG, Sullivan VJ.

Hum Vaccin. 2007 May-Jun;3(3):90-3.

PMID:
17375001
9.
10.

An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.

Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A, Richardson C.

Vaccine. 2006 May 1;24(18):3953-63.

PMID:
16530302
11.

Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.

Mendelson I, Gat O, Aloni-Grinstein R, Altboum Z, Inbar I, Kronman C, Bar-Haim E, Cohen S, Velan B, Shafferman A.

Vaccine. 2005 Dec 1;23(48-49):5688-97.

PMID:
16039760
12.

A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P.

Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13601-6.

13.

Detoxified lethal toxin as a potential mucosal vaccine against anthrax.

Xu Q, Zeng M.

Clin Vaccine Immunol. 2008 Apr;15(4):612-6. doi: 10.1128/CVI.00402-07.

14.
15.

Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine.

Marcus H, Danieli R, Epstein E, Velan B, Shafferman A, Reuveny S.

Infect Immun. 2004 Jun;72(6):3471-7.

16.

Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids.

Enkhtuya J, Kawamoto K, Kobayashi Y, Uchida I, Rana N, Makino S.

Microbiology. 2006 Oct;152(Pt 10):3103-10.

PMID:
17005989
17.

Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.

Baillie LW, Rodriguez AL, Moore S, Atkins HS, Feng C, Nataro JP, Pasetti MF.

Vaccine. 2008 Nov 11;26(48):6083-91. doi: 10.1016/j.vaccine.2008.09.010.

18.
19.

Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.

Flick-Smith HC, Eyles JE, Hebdon R, Waters EL, Beedham RJ, Stagg TJ, Miller J, Alpar HO, Baillie LW, Williamson ED.

Infect Immun. 2002 Apr;70(4):2022-8.

20.

Protective effect of Bacillus anthracis surface protein EA1 against anthrax in mice.

Uchida M, Harada T, Enkhtuya J, Kusumoto A, Kobayashi Y, Chiba S, Shyaka A, Kawamoto K.

Biochem Biophys Res Commun. 2012 May 4;421(2):323-8. doi: 10.1016/j.bbrc.2012.04.007.

PMID:
22507985
Items per page

Supplemental Content

Support Center